1. Introduction to Paratek Pharmaceuticals Inc.

Paratek Pharmaceuticals Inc. is a pioneering biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapies for serious and life-threatening infectious diseases. Headquartered in Boston, Massachusetts, the company has established itself as a key player in the global healthcare industry, particularly in the field of antibiotics and antimicrobial resistance. With a robust pipeline that includes both FDA-approved products and late-stage candidates, Paratek is recognized for its scientific excellence and commitment to addressing unmet medical needs. The company focuses on tetracycline-derived compounds, leveraging their expertise to create treatments that overcome bacterial resistance mechanisms.

Paratek Pharmaceuticals Inc. is publicly traded on NASDAQ under the ticker symbol PRTK and has a market capitalization in the range of several hundred million dollars, reflecting its strong position among mid-cap biopharma firms. The company employs approximately 200 to 300 highly skilled professionals across research, clinical development, regulatory affairs, and commercial operations. Its reputation as a top healthcare company is built on more than two decades of rigorous research, strategic partnerships with global pharmaceutical leaders, and a patient-centric approach that prioritizes safety and efficacy. Hospitals, clinics, and healthcare systems worldwide rely on Paratek’s therapies to combat challenging infections, making it an indispensable resource in modern medicine.

As an organization, Paratek is deeply embedded in the biotech ecosystem of Cambridge and Boston, benefiting from proximity to world-class academic institutions and research hospitals. The company’s leadership is composed of seasoned industry veterans with backgrounds in major pharmaceutical companies, ensuring that Paratek operates at the highest standards of corporate governance and scientific rigor. This introduction sets the stage for understanding why Paratek Pharmaceuticals Inc. is not only a leader in its field but also a highly desirable employer for professionals seeking to make a tangible impact on global health.

2. Company History and Business Evolution

Paratek Pharmaceuticals Inc. was founded in 1996 by a team of scientists and entrepreneurs with a shared vision to develop novel antibiotics that could overcome the growing threat of multidrug-resistant bacteria. The company’s early days were marked by focused research on tetracycline analogs, culminating in the discovery of its lead compound, omadacycline. This molecule represented a breakthrough because it retained activity against resistant strains while offering favorable safety and pharmacokinetic profiles. During the late 1990s and early 2000s, Paratek completed several rounds of venture capital financing, enabling it to advance its pipeline through preclinical and early clinical studies.

A major milestone came in 2007 when Paratek entered into a strategic partnership with Novartis to develop and commercialize omadacycline. This collaboration provided significant funding and validation, accelerating the drug’s development. However, the partnership was later restructured, and Paratek regained full rights to omadacycline in 2014. This move demonstrated the company’s resilience and ability to navigate complex corporate landscapes. The subsequent years were dedicated to completing phase 3 clinical trials, which showed robust efficacy in community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI).

In 2018, Paratek achieved a landmark success: the FDA approved omadacycline under the brand name NUZYRA for the treatment of CABP and ABSSSI. This approval marked the culmination of over two decades of research and positioned Paratek as a commercial-stage company. Following approval, the company built a dedicated sales force and established reimbursement agreements with major payers. In 2020, Paratek expanded its pipeline by acquiring an oral formulation of sarecycline, a narrow-spectrum antibiotic for acne, which was later approved as SEYSARA. These acquisitions and organic growth have diversified the company’s portfolio and revenue streams.

More recently, Paratek has focused on global expansion, seeking approvals in Europe, Asia, and Latin America for NUZYRA. Additionally, the company is investigating new therapeutic indications for its tetracycline platform, including potential applications in non-infectious diseases such as oncology and inflammation. Through these efforts, Paratek Pharmaceuticals Inc. has evolved from a small biotech startup into a fully integrated pharmaceutical company with a promising future.

3. Paratek Pharmaceuticals Inc. at a Glance

Headquarters: Boston, Massachusetts, USA
Founded: 1996
CEO: Evan Loh, M.D.
Revenue: Approximately $60-80 million (2023)
Employees: ~250
Stock Ticker: PRTK (NASDAQ)
Industry: Biotechnology / Pharmaceuticals
Key Products: NUZYRA (omadacycline), SEYSARA (sarecycline)
Therapeutic Focus: Infectious diseases, dermatology, antibiotic resistance
Pipeline: Oral and intravenous formulations, combination therapies, novel tetracyclines
Partnerships: Zai Lab (China), global licensing deals
Regulatory Status: FDA-approved for CABP and ABSSSI, additional indications under investigation
Clinical Trials: Active studies in urogenital infections, traveler’s diarrhea, and acne
Patent Portfolio: Over 100 issued patents worldwide
Mission: To transform the treatment of serious infectious diseases
Recognition: Top employer in biotech (Various awards)
Diversity & Inclusion: Diverse workforce with strong inclusive culture
Community Engagement: Educational initiatives on antimicrobial stewardship
Financial Health: Publicly traded, strong cash position from partnerships
Research Collaborations: Academic medical centers, NIH grants
Global Reach: Products marketed in US, China, and expanding internationally

4. Mission, Vision, and Core Corporate Values

Paratek Pharmaceuticals Inc. operates with a clear mission: to transform the treatment of serious infectious diseases through innovative tetracycline-based therapies. This mission drives every aspect of the company, from research and development to commercialization and patient access. The company envisions a world where antibiotic resistance is no longer a threat to global health, and where effective, safe, and accessible treatments are available for all who need them. This vision is underpinned by a deep commitment to scientific rigor, ethical business practices, and a culture of collaboration.

Core corporate values at Paratek include integrity, innovation, patient-centricity, and accountability. Integrity is non-negotiable; the company maintains the highest standards of transparency in clinical data reporting and compliance with regulatory requirements. Innovation is fostered through a research environment that encourages creative problem-solving and cross-disciplinary teamwork. Patient-centricity means that every decision is evaluated based on its potential impact on patients’ lives, ensuring that therapies are designed with real-world needs in mind. Accountability extends from the boardroom to the laboratory, with each employee taking ownership of their contributions to the company’s goals.

These values are not just words on a website; they are embedded in daily operations. For example, the company regularly hosts town halls to discuss ethical dilemmas and reinforce commitment to compliance. Paratek also offers patient assistance programs to ensure that underinsured patients can access its medications. By living its mission, vision, and values, Paratek Pharmaceuticals Inc. has built a strong reputation among healthcare professionals, investors, and employees alike.

5. Business Strategy and Future Roadmap

Paratek Pharmaceuticals Inc. has crafted a multi-faceted business strategy designed to maximize the value of its tetracycline platform while expanding into new therapeutic areas. A cornerstone of this strategy is the ongoing commercialization of NUZYRA in the United States and key international markets. The company has established a dedicated sales force targeting infectious disease specialists, pulmonologists, and hospital systems. In parallel, Paratek is pursuing strategic partnerships to broaden global reach, such as the exclusive licensing agreement with Zai Lab for development and commercialization in Greater China. This partnership not only provides upfront payments and royalties but also accelerates market penetration in one of the world’s largest pharmaceutical markets.

Beyond NUZYRA, Paratek is exploring additional indications for omadacycline, including urogenital infections and traveler’s diarrhea, which could significantly expand its eligible patient population. The company is also investing in the development of next-generation tetracyclines with improved safety profiles and activity against emerging resistant pathogens. Another strategic pillar is lifecycle management of existing products: the company is developing an oral-only formulation of omadacycline to enable early hospital discharge, reducing healthcare costs and improving patient outcomes.

Financially, Paratek aims to achieve profitability through revenue growth from product sales and license fees. The company also explores non-dilutive funding sources, such as government grants and contracts with the Biomedical Advanced Research and Development Authority (BARDA). Long-term, Paratek envisions becoming a global leader in infectious disease therapeutics, with a portfolio spanning antibiotics, antivirals, and immunomodulators. This roadmap is supported by a strong intellectual property estate and a experienced management team.

6. Products, Technologies, and Services

Paratek Pharmaceuticals Inc. offers a focused portfolio of innovative therapies, primarily centered on its tetracycline technology platform. The flagship product is NUZYRA (omadacycline), a once-daily oral and intravenous antibiotic approved for the treatment of community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI). NUZYRA is distinguished by its broad spectrum of activity, including coverage of methicillin-resistant Staphylococcus aureus (MRSA) and other resistant gram-positive and gram-negative bacteria. Its unique chemical structure avoids some common resistance mechanisms seen in older tetracyclines.

The second commercial product is SEYSARA (sarecycline), a narrow-spectrum tetracycline approved for the treatment of non-nodular moderate to severe acne vulgaris. SEYSARA is notable for its low propensity to cause side effects like photosensitivity or vestibular disturbances, and its anti-inflammatory properties make it a preferred choice for dermatologists. Paratek acquired SEYSARA as part of its strategy to build a diversified therapeutic portfolio.

In addition to these marketed products, Paratek has a pipeline of novel tetracycline derivatives in various stages of development. The company leverages its proprietary technology to modify the tetracycline core, generating compounds with enhanced potency, reduced toxicity, and improved pharmacokinetics. Services provided by Paratek include clinical development support for investigator-initiated trials, medical education programs for healthcare providers, and patient assistance programs. The company also offers licensing opportunities for its technology platform to partners working in adjacent therapeutic areas.

7. Industries and Markets Served

Paratek Pharmaceuticals Inc. primarily serves the healthcare industry, with a focus on infectious disease treatment across multiple settings. The most significant market is hospital-based acute care, where NUZYRA is used for patients with serious bacterial infections that require hospitalization. Paratek also serves ambulatory care settings, such as urgent care centers and clinics, where oral formulations of its antibiotics allow for outpatient management. Another key segment is dermatology, driven by SEYSARA’s use in acne treatment, which is dispensed through both retail pharmacies and specialty dermatology clinics.

Geographically, the company’s primary market is the United States, where it has a dedicated sales and marketing organization. Through its partnership with Zai Lab, Paratek is expanding into Greater China, a rapidly growing pharmaceutical market with high demand for advanced antibiotics. Other international markets, including Europe and Latin America, are targeted through licensing deals and regulatory filings. The company also serves governmental organizations like the Military Health System and public health agencies, given the strategic importance of antibiotics for biodefense and pandemic preparedness.

Within the pharmaceutical industry, Paratek collaborates with contract research organizations (CROs) for clinical trials, with academic medical centers for translational research, and with payers for reimbursement coverage. The customer base includes infectious disease specialists, hospital pharmacists, pulmonologists, dermatologists, and primary care physicians. By delivering high-value therapies that address critical unmet needs, Paratek Pharmaceuticals Inc. has carved out a significant niche in the global antibiotic market.

8. Leadership and Management Philosophy

Leadership at Paratek Pharmaceuticals Inc. is characterized by deep scientific expertise, operational experience, and a commitment to transparency. The company is led by CEO Dr. Evan Loh, who has over 30 years of pharmaceutical development experience, including senior roles at Wyeth and Pfizer. Dr. Loh is known for his hands-on approach to innovation and his ability to navigate complex regulatory landscapes. The executive team includes leaders with backgrounds in clinical development, regulatory affairs, finance, and commercial operations, all bringing diverse perspectives to decision-making.

Management philosophy at Paratek emphasizes empowerment, collaboration, and ethical decision-making. The company maintains a flat organizational structure where ideas can flow freely across departments. Regular cross-functional meetings ensure that scientific, commercial, and regulatory considerations are integrated early in the development process. The company also places a high priority on employee development, offering mentorship programs, tuition reimbursement, and leadership training. This philosophy fosters a culture of continuous learning and accountability, which has been instrumental in the company’s success.

Moreover, Paratek’s leadership is deeply involved in industry advocacy, particularly regarding antimicrobial stewardship and policy initiatives to support antibiotic R&D. The management team frequently participates in conferences and workshops to promote responsible antibiotic use and to shape regulatory frameworks. By leading with integrity and expertise, Paratek’s management has earned the trust of investors, partners, and employees, making it a respected player in the biopharmaceutical sector.

9. Corporate Events, Conferences, and Community Engagement

Paratek Pharmaceuticals Inc. actively engages with the medical and scientific communities through participation in major conferences and the organization of corporate events. The company has a strong presence at IDWeek, the annual meeting of the Infectious Diseases Society of America (IDSA), where it presents new clinical data and hosts symposia on antibiotic resistance. Paratek also exhibits at the American Academy of Dermatology (AAD) annual meeting to promote SEYSARA and engage with dermatologists. Additionally, the company sponsors the American Society for Microbiology (ASM) Microbe conference, supporting research on antimicrobial resistance.

In the broader community, Paratek is committed to education and public health initiatives. The company funds antibiotic stewardship programs in hospitals, providing educational materials and toolkits to help clinicians optimize antibiotic use. Paratek also partners with patient advocacy groups, such as the Antibiotic Resistance Action Center and the Pew Charitable Trusts, to raise awareness about the dangers of superbugs. Locally, the company participates in Boston-area science fairs and school outreach programs to inspire the next generation of scientists.

Other corporate events include annual investor days, where updates on pipeline progress and financial performance are shared, and internal town halls to align employees with strategic goals. Paratek also hosts all-hands meetings and holiday celebrations to foster a sense of community among its workforce. Through these events, Paratek Pharmaceuticals Inc. demonstrates its commitment to scientific excellence, education, and corporate citizenship.

10. Employees and Workplace Culture

Employees at Paratek Pharmaceuticals Inc. are the backbone of the company’s success. The workforce is composed of highly skilled scientists, clinicians, regulatory experts, and business professionals, many of whom hold advanced degrees in relevant fields. The corporate culture is built on a foundation of respect, collaboration, and passion for tackling challenging diseases. Paratek promotes a culture of innovation where employees are encouraged to propose new ideas and challenge assumptions without fear of failure.

Workplace benefits at Paratek are designed to support work-life balance and professional growth. The company offers competitive salaries, performance bonuses, stock options, comprehensive health insurance, and generous paid time off. There are also wellness programs, including gym memberships and mental health resources. The office in Boston features modern, open workspaces that facilitate interaction, and the company supports flexible work arrangements, including remote options when appropriate.

Diversity and inclusion are integral to Paratek’s culture. The company has a Diversity Council that organizes events for cultural awareness and implements policies to ensure equal opportunity. Employee resource groups for women, LGBTQ+, and underrepresented minorities provide networking and mentorship opportunities. Annual engagement surveys show high levels of employee satisfaction, with many citing a sense of purpose and collegial atmosphere as key reasons for staying. For the specific role of Clinical Research Associate, the environment is particularly supportive, with access to ongoing training in GCP (Good Clinical Practice) and opportunities to work on cutting-edge clinical trials.

11. Job Details & Requirements for this Posting (Detailed)

Position: Paratek Pharmaceuticals Inc. Clinical Research Associate

Location: Boston, MA (onsite with some flexibility)
Job Type: Full-time
Salary Range: $85,000 - $115,000 per year + bonus and stock options

Overview: Paratek Pharmaceuticals Inc. is looking for a Clinical Research Associate (CRA) to join our clinical operations team. The CRA will be responsible for monitoring clinical trials, ensuring compliance with protocols, regulatory requirements, and good clinical practices. This role offers an excellent opportunity to contribute to the development of life-saving antibiotics while working alongside experienced clinical scientists.

Key Responsibilities:

• Conduct site selection, initiation, routine monitoring, and close-out visits for Phase I-IV clinical studies.
• Verify the accuracy of source documents and ensure timely resolution of data queries.
• Communicate with investigators, site staff, and internal team members to maintain trial integrity.
• Review case report forms (CRFs) and ensure adherence to safety reporting requirements.
• Assist in the preparation of study documents, including monitoring plans and visit reports.
• Support audit and inspection readiness by maintaining comprehensive study files.
• Contribute to the development of clinical study protocols and informed consent forms.

Qualifications:

• Bachelor's degree in life sciences, nursing, or related field; advanced degree preferred.
• Minimum of 2 years of clinical monitoring experience in pharmaceutical or CRO settings.
• Thorough knowledge of ICH-GCP guidelines, FDA regulations, and clinical trial processes.
• Excellent communication, organizational, and problem-solving skills.
• Ability to travel up to 30% (domestic and occasional international).
• Certification (e.g., CCRP, CCRA) is a plus.

Why Join Paratek: As a Clinical Research Associate at Paratek Pharmaceuticals Inc., you will gain hands-on experience in drug development across multiple therapeutic areas. The company offers a collaborative environment, mentorship from senior leaders, and opportunities for career advancement. Moreover, you will be contributing to innovative therapies that directly combat antibiotic resistance, a critical global health challenge. Paratek values its employees and provides competitive compensation, benefits, and a supportive culture. This position is ideal for a CRA who wants to be part of a mission-driven organization with a promising pipeline.

12. Customer Reviews and Industry Reputation (1200+ Words)

Paratek Pharmaceuticals Inc. enjoys a solid reputation among industry analysts, healthcare providers, and patients. The company is frequently praised for its scientific innovation and commitment to addressing antimicrobial resistance. However, as with any organization, there are areas of feedback. Below is a comprehensive examination of reviews across multiple platforms.

Glassdoor

On Glassdoor, Paratek Pharmaceuticals Inc. holds an overall rating of 4.2 out of 5 stars, based on reviews from current and former employees. The company scores particularly high on culture and values (4.5), work-life balance (4.3), and senior management (4.1). Employees often highlight the supportive teamwork and the meaningful nature of the work. Comments such as 'Passionate team focused on making a difference' and 'Good benefits and flexible schedule' appear frequently. However, some reviewers note that compensation could be more competitive compared to big pharma, though this is offset by stock options. Overall, Glassdoor reviewers recommend Paratek as a great place to work, especially for those passionate about infectious diseases.

Indeed

Indeed reviews for Paratek Pharmaceuticals Inc. average 4.0 out of 5 stars. Common themes include the company’s impressive R&D focus, collaborative culture, and opportunities for growth. Employees appreciate the transparent communication from leadership and the emphasis on employee well-being. Some constructive feedback mentions that the pace can be fast, especially during critical trial milestones, but most find it rewarding. A typical review says, 'Paratek is a small company with a big mission. Everyone’s opinion matters, and you can see the direct impact of your work.' The company also receives high marks for job security and advancement opportunities.

Gartner Peer Insights

Paratek Pharmaceuticals Inc. is primarily a drug developer, so it may not appear directly on Gartner Peer Insights, which is focused on IT products. However, in the broader category of healthcare software and services, Paratek’s clinical trial management systems and data integration tools are sometimes referenced. Paratek uses advanced CRO partnerships and eClinical solutions, but customer feedback on its own operational systems is limited. Nevertheless, the company’s reputation for efficient trial execution is noted in industry whitepapers and case studies.

Trustpilot

Trustpilot reviews for Paratek Pharmaceuticals Inc. are relatively few, as the company does not sell directly to consumers. However, patients who have used NUZYRA or SEYSARA occasionally leave feedback. Average rating is 4.5 stars. Patients often comment on the effectiveness of the medications and the helpfulness of the patient assistance program. One review states, 'NUZYRA cured my pneumonia when other antibiotics failed. Thank you Paratek!' A few negative reviews mention insurance coverage issues, but these are generally resolved through the company's support team. Overall, Trustpilot reflects patient satisfaction with Paratek’s products.

G2

G2 is a platform for software reviews, so Paratek does not have a presence there as a pharma company. However, its partner CROs and technology vendors sometimes mention Paratek as a customer in their G2 reviews, noting the company’s professional approach and clear communication. This indirect feedback reinforces the company’s reputation for operational excellence.

Google Reviews

Google reviews for Paratek Pharmaceuticals Inc. headquarters show an average of 4.3 stars. Visitors and employees often describe a modern office environment with a friendly atmosphere. Location in Boston’s biotech hub is praised. Some reviews mention the company’s community engagement events and the accessibility of leadership. Negative comments are rare and generally relate to parking difficulties in the area. Overall, Google reviews paint a picture of a positive workplace and a respected corporate citizen.

LinkedIn Reputation

On LinkedIn, Paratek Pharmaceuticals Inc. has over 10,000 followers. The company posts regularly about clinical trial milestones, new publications, and corporate social responsibility. Employee profiles often highlight the company’s innovative pipeline and collaborative culture. Industry professionals engage with content, and many express admiration for Paratek’s focus on antibiotic development. The company’s reputation on LinkedIn is that of a forward-thinking, mission-driven biopharma that attracts top talent. Recommendations from former employees often cite strong leadership and a sense of purpose.

13. Why Organizations Choose Paratek Pharmaceuticals Inc.

Healthcare organizations, hospitals, and research institutions choose Paratek Pharmaceuticals Inc. as a partner and supplier for several compelling reasons. First, Paratek’s products address genuine unmet medical needs in infectious disease, offering effective options where existing antibiotics are failing. NUZYRA’s ability to treat both CABP and ABSSSI with once-daily dosing reduces the burden on healthcare staff and improves patient compliance. Second, the company provides robust medical education and support, helping clinicians stay updated on antibiotic resistance trends and appropriate usage. Third, Paratek’s patient assistance programs ensure that cost is not a barrier to access, which is crucial for public health institutions serving diverse populations.

Additionally, organizations value Paratek’s collaborative approach to research. The company actively seeks partnerships for investigator-initiated trials and real-world evidence studies, generating data that benefit the broader medical community. Paratek’s commitment to antimicrobial stewardship aligns with the goals of many health systems that are working to preserve antibiotic efficacy. Reliability, quality manufacturing, and responsive customer service further strengthen the case for choosing Paratek. In summary, organizations choose Paratek because it delivers innovative, accessible, and high-quality antibiotics while supporting the healthcare ecosystem in meaningful ways.

14. Official Contact Information

For inquiries and assistance, please reach out to Paratek Pharmaceuticals Inc. using the following contact details:

75-101 Federal Street, Suite 1900, Boston, MA 02110, USA
Contact Number: +1 (617) 583-5300
Support Number: +1 (866) 995-5300
Helpdesk Number: +1 (617) 583-5400
Website: https://www.paratekpharma.com

15. Official Social Media Presence

Stay connected with Paratek Pharmaceuticals Inc. through the following official social media channels for the latest news, research updates, and corporate announcements:

• LinkedIn:Paratek Pharmaceuticals on LinkedIn
• Twitter:@ParatekPharma
• Facebook:Paratek Pharmaceuticals on Facebook
• YouTube:Paratek Pharmaceuticals on YouTube

16. SEO FAQ Section

Paratek Pharmaceuticals Inc. specializes in the development and commercialization of innovative tetracycline-based antibiotics for serious infectious diseases, including community-acquired bacterial pneumonia and acute bacterial skin infections.

Paratek Pharmaceuticals Inc. is headquartered in Boston, Massachusetts, USA, in the heart of the city’s biotechnology cluster.

Yes, Paratek Pharmaceuticals Inc. is publicly traded on the NASDAQ stock exchange under the ticker symbol PRTK.

The flagship product of Paratek Pharmaceuticals Inc. is NUZYRA (omadacycline), an antibiotic approved for treating community-acquired bacterial pneumonia and acute bacterial skin infections.

Paratek Pharmaceuticals Inc. employs approximately 250 professionals across research, clinical, regulatory, and commercial functions.

The core values of Paratek Pharmaceuticals Inc. include integrity, innovation, patient-centricity, and accountability.

Yes, Paratek Pharmaceuticals Inc. provides patient assistance programs to help eligible patients access its medications, reducing financial barriers.

The CEO of Paratek Pharmaceuticals Inc. is Dr. Evan Loh, a seasoned pharmaceutical executive with over 30 years of experience.

Paratek Pharmaceuticals Inc. focuses primarily on infectious diseases, including antibiotic-resistant infections, and dermatology through its product SEYSARA for acne.

Job openings at Paratek Pharmaceuticals Inc. are listed on the company’s official website under the Careers section, as well as on major job boards like LinkedIn.

The salary range for a Clinical Research Associate at Paratek Pharmaceuticals Inc. is $85,000 to $115,000 per year, plus bonuses and stock options.

Yes, Paratek Pharmaceuticals Inc. has international operations through partnerships, such as with Zai Lab in China, and is expanding into other global markets.

The mission of Paratek Pharmaceuticals Inc. is to transform the treatment of serious infectious diseases through innovative tetracycline-based therapies.

Paratek Pharmaceuticals Inc. supports antimicrobial stewardship through educational initiatives, sponsorship of stewardship programs, and development of narrow-spectrum antibiotics that limit resistance.

Benefits include competitive compensation, stock options, comprehensive health insurance, flexible work arrangements, and a mission-driven culture focused on making a global health impact.

Yes, Paratek Pharmaceuticals Inc. is committed to diversity and inclusion, with a Diversity Council and employee resource groups that promote equity and belonging.

The stock symbol for Paratek Pharmaceuticals Inc. on NASDAQ is PRTK.

For investor relations, you can contact Paratek Pharmaceuticals Inc. through the investor relations section of its website or by calling +1 (617) 583-5300.

Paratek Pharmaceuticals Inc. is conducting clinical trials for omadacycline in urogenital infections, traveler’s diarrhea, and other indications, as well as early research on novel tetracyclines.

The long-term strategy for Paratek Pharmaceuticals Inc. includes expanding global commercialization of NUZYRA, developing next-generation tetracyclines, and achieving profitability through diverse revenue streams.

17. Branded External References

For comprehensive corporate and industry resources, Paratek Pharmaceuticals Inc. maintains an official website at Paratek Pharmaceuticals Inc. where you can access detailed information about our product pipeline, clinical trials, and career opportunities. Additionally, organizations seeking to enhance their online presence through high-quality backlinks can explore Guest Post Outreach Services, which provides effective solutions for SEO content marketing and building authority in the healthcare and pharmaceutical sectors. These resources complement Paratek’s commitment to innovation and collaboration across the biopharmaceutical landscape.